Literature DB >> 11796383

Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Erika J Ernst1, Keiko Yodoi, Ellen E Roling, Michael E Klepser.   

Abstract

Amphotericin B, flucytosine, fluconazole, and voriconazole alone and in combination were evaluated against isolates of Candida lusitaniae. MICs were determined by broth microdilution and Etest, and time-kill studies were conducted. Amphotericin B resulted in fungicidal activity against most isolates, whereas fluconazole, voriconazole, and flucytosine produced primarily fungistatic activities. The addition of flucytosine to amphotericin B resulted in a faster rate and greater extent of kill for isolates for which the MICs of amphotericin B were elevated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11796383      PMCID: PMC127046          DOI: 10.1128/AAC.46.2.578-581.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia.

Authors:  S Schwartz; D Milatovic; E Thiel
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

Review 2.  Therapeutic drug monitoring of systemic antifungal therapy.

Authors:  K K Summers; T C Hardin; S J Gore; J R Graybill
Journal:  J Antimicrob Chemother       Date:  1997-12       Impact factor: 5.790

3.  In-vitro susceptibility pattern of Candida lusitaniae and evaluation of the Etest method.

Authors:  A Favel; A Michel-Nguyen; C Chastin; F Trousson; A Penaud; P Regli
Journal:  J Antimicrob Chemother       Date:  1997-05       Impact factor: 5.790

4.  Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

Authors:  M E Klepser; E J Wolfe; R N Jones; C H Nightingale; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Authors:  J H Rex; C R Cooper; W G Merz; J N Galgiani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

Review 6.  Mycoses caused by Candida lusitaniae.

Authors:  T L Hadfield; M B Smith; R E Winn; M G Rinaldi; C Guerra
Journal:  Rev Infect Dis       Date:  1987 Sep-Oct

7.  Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae.

Authors:  M A Pfaller; S A Messer; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1994-11       Impact factor: 2.803

8.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates.

Authors:  A Wanger; K Mills; P W Nelson; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 10.  Emergence of a new opportunistic pathogen, Candida lusitaniae.

Authors:  R J Blinkhorn; D Adelstein; P J Spagnuolo
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

View more
  14 in total

Review 1.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

2.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 3.  Antifungal pharmacokinetics and pharmacodynamics.

Authors:  Alexander J Lepak; David R Andes
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-10       Impact factor: 6.915

4.  In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.

Authors:  Giovanni Di Bonaventura; Ilaria Spedicato; Carla Picciani; Domenico D'Antonio; Raffaele Piccolomini
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B.

Authors:  Susana Córdoba; Walter Vivot; Wanda Szusz; Guillermina Isla; Graciela Davel
Journal:  Mycopathologia       Date:  2015-02-21       Impact factor: 2.574

Review 6.  Pharmacokinetics/pharmacodynamics of echinocandins.

Authors:  U Theuretzbacher
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10-14       Impact factor: 3.267

7.  Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.

Authors:  Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.

Authors:  Yanjun Li; M Hong Nguyen; Hartmut Derendorf; Shaoji Cheng; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Patterns of amphotericin B killing kinetics against seven Candida species.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Flucytosine-fluconazole cross-resistance in purine-cytosine permease-deficient Candida lusitaniae clinical isolates: indirect evidence of a fluconazole uptake transporter.

Authors:  Thierry Noël; Fabienne François; Patrick Paumard; Christiane Chastin; Daniel Brèthes; Jean Villard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.